A year after the US Federal Trade Commission set its sights on pharmaceutical mergers, the agency has teamed up with the Department of Justice for a broad review of their merger guidelines. The new initiative once again shows that mergers in pharma and other industries may face additional hurdles.
On 18 January, the FTC and DOJ issued a request for information seeking public comment on how they can modernize enforcement of antitrust laws in mergers
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?